Updated recommendations for the use of pneumococcal polysaccharide vaccine.
Miazga
Elizabeth J
EJ
School of Pharmacy, University of Wisconsin-Madison, USA. mshayney@pharmacy.wisc.edu
Biesboer
Ann N
AN
Hayney
Mary S
MS
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000150:complications; D002648:Child; D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007198:Indians, North American; D004930:Inuit; D008875:Middle Aged; D010353:Patient Education as Topic; D010593:Pharmaceutical Services / Q000458:organization & administration; D011008:Pneumococcal Infections / Q000150:complications / Q000208:ethnology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012907:Smoking / Q000009:adverse effects; D014481:United States; D055815:Young Adult
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines